{
    "organizations": [],
    "uuid": "3e26b7d952684f728c6b59f6db1a27ca51b16b03",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cytomx-therapeutics-q1-revenue-142/brief-cytomx-therapeutics-q1-revenue-14-2-mln-vs-i-b-e-s-view-16-4-mln-idUSASC0A147",
    "ord_in_thread": 0,
    "title": "BRIEF-CytomX Therapeutics Q1 Revenue $14.2 Mln Vs I/B/E/S View $16.4 Mln",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 9 (Reuters) - CytomX Therapeutics Inc:\n* CYTOMX THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS\n* Q1 REVENUE $14.2 MILLION VERSUS I/B/E/S VIEW $16.4 MILLION\n* QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.40 * Q1 EARNINGS PER SHARE VIEW $-0.44, REVENUE VIEW $16.4 MILLION â€” THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-10T04:17:00.000+03:00",
    "crawled": "2018-05-10T17:20:09.068+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "cytomx",
        "therapeutic",
        "inc",
        "cytomx",
        "therapeutic",
        "announces",
        "first",
        "quarter",
        "financial",
        "result",
        "q1",
        "revenue",
        "million",
        "versus",
        "view",
        "million",
        "qtrly",
        "net",
        "loss",
        "per",
        "share",
        "basic",
        "diluted",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}